Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Avid Bioservices Downgraded to Hold From Buy at Craig-Hallum
RBC Capital Downgrades Avid Bioservices(CDMO.US) to Hold Rating, Raises Target Price to $12.5
Avid Bioservices Analyst Ratings
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating, Announces Target Price $16
RBC Capital Maintains Avid Bioservices(CDMO.US) With Buy Rating, Raises Target Price to $12
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Initiates Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on Avid Bioservices (CDMO)
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)